Pfizer Inc. (PFE)
NYSE: PFE · Pharmaceutical Preparations · New York, NY · filing with the SEC since 1994
Grade5.9
◀ Past 6.7● Present 6.7▶ Future 4.1
Who owns Pfizer Inc.
As filed with the SECHolders of 5% or more
1
Vanguard Capital Management holds 7.51% of Common Stock, as its SCHEDULE 13G filed May 1, 2026 says.
Directors and officers
24
report now, of 49 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 1 named at left.
Holders of 5% or moreshare of the class, as filed
Vanguard Capital Management
SCHEDULE 13G · filed May 1, 2026 · Common Stock
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
What PFE reports owning in othersstakes of 5% or more, and other ties
Allogene Therapeutics, Inc. ALLO
SCHEDULE 13D/A · filed Feb 13, 2026 · Common Stock, par value $0.001 per share (the "Common Stock")
Trex Bio, Inc.
SCHEDULE 13G · filed Oct 16, 2026 · Common Stock par value $0.0001 per share
Zura Bio Limited ZURA
SCHEDULE 13G/A · filed Feb 12, 2025 · Class A Ordinary Shares, $0.0001 par value per share · reported falling below 5%
Cardiff Oncology, Inc. CRDF
SCHEDULE 13G/A · filed Feb 12, 2025 · Common Stock, $0.0001 par value per share · reported falling below 5%
Oric Pharmaceuticals, Inc. ORIC
SCHEDULE 13G/A · filed May 12, 2026 · Common Stock par value $0.0001 per share · reported falling below 5%
NextCure, Inc. NXTC
SCHEDULE 13G/A · filed Feb 13, 2026 · Common Stock par value $0.001 per share · reported falling below 5%
Q32 Bio Inc. QTTB
SCHEDULE 13G/A · filed Feb 13, 2026 · Common Stock par value $0.0001 per share · reported falling below 5%
Haleon plc HLN
SCHEDULE 13D/A · filed Mar 24, 2025 · Ordinary Shares, nominal value GBP0.01 per share · reported falling below 5%
Other ties the annual report names
Haleon
An investee · investee · invested in, named in the 10-K filed Feb 26, 2026
ViiV Healthcare Limited
An investee · investee · invested in, named in the 10-K filed Feb 26, 2026
Metsera
A company bought · acquisition · Oct 2025 · owns, named in the 10-K filed Feb 26, 2026
Seagen
A company bought · acquisition · Nov 2023 · owns, named in the 10-K filed Feb 26, 2026
285 subsidiaries in 68 countries, from the list filed with the 10-K filed Feb 26, 2026. Its Form 13F-HR for Jun 30, 2026 lists 17 holdings. The record carries no value for them.
Insider tradesForm 4
2sales
3purchases
0sales on a scheduled plan
1people selling
$100,000sold, in dollars
$3.0Mbought, in dollars
Open-market trades on Form 4 from Nov 3, 2025 to Nov 3, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 3, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window4 of 49 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Damico Jennifer B. | SVP & Controller | 2 | $100,000 | 0 | 0 | $0 |
| Bourla Albert | Chairman & CEO | 0 | $0 | 0 | 1 | $1.0M |
| Buckley Mortimer J | director | 0 | $0 | 0 | 1 | $1.0M |
| Blaylock Ronald E | director | 0 | $0 | 0 | 1 | $1.0M |